Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial
ConclusionIn the BRAVO 3 trial, AKI occurred in 17% at 30 days and in 10.7% at 7 days. AKI was associated with a significantly greater adjusted risk for 30-day death. Multivariate predictors of AKI at 30 days included baseline hemoglobin, body weight, and prior coronary artery disease, and predictors at 7 days included pre-existing vascular disease, C KD, transfusion, and valve post-dilation. Bivalirudin was associated with greater AKI within 48 h in the intention to treat but not in the per-protocol analysis.Graphic abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Academia | Angiomax | Bleeding | Cardiology | Chronic Kidney Disease | Heart | Heart Valve Surgery | Urology & Nephrology | Women